相关实验视频
Updated: Jul 20, 2025

06:33
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
7.8K
对α-1抗素缺乏症的诊断和增强疗法:当前的知识和未来的潜在潜力
1Pneumology Service, Hospital Regional da Asa Norte, Brasília, Brazil.
Drugs in context
|July 31, 2023
概括
阿尔法-1抗素缺乏症 (AATD) 是一种被诊断不足的遗传性肺和肝病. 增强疗法可以通过增加AAT水平和减少肺炎来减缓疾病的进展.
科学领域:
- 肺部病理学 肺部病理学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔法-1抗素缺乏症 (AATD) 是一种罕见的自体遗传性疾病.
- 它显著增加了对肺气和肝脏疾病的易感性.
- 尽管已被认可多年,但AATD仍然被诊断不足,阻碍了有效的治疗.
研究的目的:
- 审查AATD的疾病过程,诊断和治疗.
- 评估AAT增强疗法在管理AATD方面的疗效.
- 评估增强疗法对疾病进展和患者结果的影响.
主要方法:
- 对AATD.现有文献的审查.
- 对AAT增强疗法机制和效果的分析.
- 评估与增强疗法相关的临床结果.
主要成果:
- AAT增强疗法增加了血清和肺的AAT水平.
- 治疗恢复了抗乳酶的能力,并减少了肺炎.
- 增强疗法减缓了肺密度的丧失,改善了诸如肺功能下降和死亡率之类的结果.
结论:
- AAT增强疗法是AATD的主要药理疗法.
- 包括初级保健在内的更广泛的测试可能会导致更早的诊断和治疗.
- 早期干预可以改善AATD诱导的肺病患者的结果.
相关概念视频
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
Cystic Fibrosis: Management
194
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
194
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
264
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
264
Alzheimer's Disease: Treatment
218
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
218
Acute Respiratory Failure-V
165
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
165

